
    
      PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by extent of disease.

      Patients are randomly assigned to oral 4-aminosalicylic acid (4-ASA) or placebo administered
      daily for 6 weeks. Optional 4-ASA is available to all patients for up to 1 year.

      Concurrent therapy with low-dose sulfasalazine, prednisone, or equivalent is allowed.
    
  